Ribomic Inc.
Notice of Revision to Earnings Guidance
Upward revision of earnings guidance for the fiscal year ending March 2027. Business revenue increased by 8 million yen from the previous forecast, operating loss improved by 69 million yen, ordinary loss improved by 103 million yen, and net loss for the period improved by 94 million yen. The revision is based on shareholder returns and restraint in R&D spending, among other factors.
Key Figures
- Key Figure 1: Business Revenue 26 million yen (Previous A: 17 million yen)
- Key Figure 2: Net Income Attributable to Owners of Parent 1,449 million yen (Previous A: 1,543 million yen, difference -94 million yen)
- Key Figure 3: Net Income Per Share 25.64 yen (Previous A: 27.96 yen, difference -2.32 yen)
AI要約
Overview of the Revision to Earnings Guidance
Following technical certification of the DDS aptamer technology within the drug discovery support business, estimates for preclinical trial costs and R&D expenses were revised, leading to an upward revision of the earnings guidance for the fiscal year ending March 2027. Revenue is expected to increase and profit-related items are generally expected to improve. The revised guidance reflects considerations such as foreign exchange and governmental subsidies and shows improvement compared to the prior-year period and the previously announced figures.
Key Points and Considerations Going Forward
The main causes of the revision include the execution of a technical evaluation agreement related to DDS aptamers, the trend in clinical costs related to RBM-006, and the impact of governmental subsidies. Actual R&D expenditure and the timing of new contract signings may cause future performance to fluctuate.
Ribomic Inc.
Company overview · Stock price · Financial data · All IR
